Research graph
References from Natural History After Likely Cure Versus Recurrence After Prostate Radiotherapy (RAPTOR). Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Follow-up of prostatectomy versus observation for early prostate cancer
10.1056/nejmoa1615869 · 2017 · External reference
Conditional risks of biochemical failure and prostate cancer–specific death in patients undergoing external beam radiotherapy: a secondary analysis of 2 randomized clinical trials
10.1001/jamanetworkopen.2023.35069 · 2023 · External reference
Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate
10.1200/jco.23.00617 · 2023 · External reference
Prostate specific antigen recurrence after definitive therapy
10.1016/j.juro.2007.01.137 · 2007 · External reference
Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: Recommended approaches and details of specific care options
10.1016/j.juro.2018.01.002 · 2018 · External reference
Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: Risk stratification, shared decision making, and care options
10.1016/j.juro.2017.11.095 · 2018 · External reference
Natural history and risk stratification of biochemically recurrent prostate cancer following definitive radiation therapy
2026 · External reference
Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy
10.1001/jamanetworkopen.2023.32900 · 2023 · External reference
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2020.09.042 · 2021 · External reference
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
10.1016/s1470-2045(21)00705-1 · 2022 · External reference
10.2307/2529934
10.2307/2529934 · External reference
Dynamic prediction by landmarking in competing risks
10.1002/sim.5665 · 2013 · External reference
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: a population-based study in Italy
10.1002/ijc.34923 · 2024 · External reference
Cancer cure for 32 cancer types: results from the EUROCARE-5 study
10.1093/ije/dyaa128 · 2020 · External reference
Defining biochemical cure after low dose rate prostate brachytherapy: external validation of 4-year prostate-specific antigen nadir as a predictor of 10- and 15-year disease-free survival
10.1016/j.clon.2021.11.009 · 2022 · External reference
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial
10.1016/s1470-2045(15)70045-8 · 2015 · External reference
Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a Phase III randomized controlled trial
10.1200/jco.19.01904 · 2019 · External reference
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer
10.1200/jco.2013.51.1972 · 2013 · External reference
Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a Phase III randomized trial
10.1200/jco.2016.70.4189 · 2017 · External reference
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
10.1016/s1470-2045(16)30102-4 · 2016 · External reference
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial
10.1016/j.ejca.2020.10.023 · 2021 · External reference
Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96–10 Trial)
10.1016/j.ijrobp.2009.12.039 · 2011 · External reference
Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991
10.1200/jco.2015.64.8055 · 2016 · External reference
10.1016/s1470-2045(18)30757-5
10.1016/s1470-2045(18)30757-5 · 2019 · External reference
Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial
10.1001/jamaoncol.2018.0039 · 2018 · External reference
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
10.1016/s1470-2045(14)70040-3 · 2014 · External reference
Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance
10.6004/jnccn.2021.7065 · 2022 · External reference
Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial
10.1001/jamanetworkopen.2020.15083 · 2020 · External reference
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
10.3324/haematol.2023.283058 · 2024 · External reference
In pursuit of a functional cure for follicular lymphoma
10.1182/hematology.2024000654 · 2024 · External reference
Prostate cancer dormancy and recurrence
10.1016/j.canlet.2021.09.037 · 2022 · External reference
The biology and clinical implications of prostate cancer dormancy and metastasis
10.1007/s00109-015-1353-4 · 2016 · External reference
Competing risks of mortality among men with biochemical recurrence after radical prostatectomy
10.1097/ju.0000000000001036 · 2020 · External reference
Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer
10.1200/jco.2022.40.6_suppl.282 · 2022 · External reference
Major patterns of cancer cure: clinical implications
2019 · External reference
Pathology grade influences competing mortality risks in elderly men with prostate cancer
10.1016/j.urolonc.2020.12.004 · 2021 · External reference
Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review
10.1016/j.eururo.2018.10.011 · 2019 · External reference
Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: analysis of randomized trial NRG/RTOG 9202
10.1200/jco.18.00154 · 2019 · External reference
A personalized clinical dynamic prediction model to characterize prognosis for patients with localized prostate cancer: analysis of the CHHiP Phase 3 trial
10.1016/j.ijrobp.2023.02.022 · 2023 · External reference
A systematic review of the evidence for the decipher genomic classifier in prostate cancer
10.1016/j.eururo.2020.11.021 · 2021 · External reference
Prostate cancer risk stratification in NRG oncology Phase III randomized trials using multimodal deep learning with digital histopathology
2024 · External reference
Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (Leviathan)
10.1016/j.eururo.2022.07.011 · 2022 · External reference
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
10.1016/j.eururo.2021.04.035 · 2021 · External reference
Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: 10-year outcomes of the FLAME trial
10.1200/jco-25-00274 · 2025 · External reference
Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer
10.1016/j.eururo.2021.12.012 · 2022 · External reference
Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread
10.1148/rg.2019180079 · 2019 · External reference
Stage migration on prostate-specific membrane antigen positron emission tomography/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the Phase 2/3 THUNDER trial
10.1016/j.euo.2025.08.005 · 2025 · External reference
